Review
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 29, 2020; 10(6): 147-161
Published online Jun 29, 2020. doi: 10.5500/wjt.v10.i6.147
Treatment options for localised renal cell carcinoma of the transplanted kidney
Gloria Motta, Mariano Ferraresso, Luca Lamperti, Dhanai Di Paolo, Nicholas Raison, Marta Perego, Evaldo Favi
Gloria Motta, Urology, IRCCS Policlinico San Donato, San Donato Milanese 27288, Italy
Mariano Ferraresso, Luca Lamperti, Dhanai Di Paolo, Marta Perego, Evaldo Favi, Renal Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
Mariano Ferraresso, Evaldo Favi, Department of Clinical Sciences and Community Health, University of Milan, Milan 20122, Italy
Nicholas Raison, MRC Centre for Transplantation, King’s College London, London WC2R 2LS, United Kingdom
Author contributions: Motta G contributed to literature review, data collection, data analysis, data interpretation, drafting the article, final approval; Ferraresso M, literature review, critical revision, and final approval; Lamperti L and Di Paolo D contributed to literature review, data collection, and final approval; Raison N contributed to drafting the article, language revision, and final approval; Perego M contributed to data collection, data analysis, editing the article, and final approval; Favi E contributed to literature review, data interpretation, drafting the article, critical revision, and final approval.
Conflict-of-interest statement: The authors do not have any conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Evaldo Favi, MD, PhD, Senior Lecturer, Surgeon, Consultant in Transplant and Vascular Access Surgery, Renal Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza n. 28, Milan 20122, Italy. evaldofavi@gmail.com
Received: February 1, 2020
Peer-review started: February 1, 2020
First decision: March 15, 2020
Revised: April 7, 2020
Accepted: May 26, 2020
Article in press: May 26, 2020
Published online: June 29, 2020
Processing time: 142 Days and 18.3 Hours
Core Tip

Core tip: Nephron-sparing surgery and ablative therapy have been increasingly recognised as a valuable alternative to transplantectomy in carefully selected kidney recipients with allograft renal cell carcinoma (RCC). The complexity of the disease, the numerosity of the treatments available, the lack of long-term follow-up data, and the relatively poor quality of the studies addressing this topic do not allow to properly define specific advantages and limitations of these conservative strategies. We performed an extensive review of the literature focusing on epidemiology, clinical presentation, diagnostic work up, staging strategies, tumour characteristics, treatment modalities, and follow-up protocols of localised RCC of the transplanted kidney.